JBC Advanced Glycation Endproducts

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M409863200 on November 1, 2004

J. Biol. Chem., Vol. 280, Issue 3, 1849-1853, January 21, 2005
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
280/3/1849    most recent
M409863200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Qing, Y.
Right arrow Articles by Stark, G. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Qing, Y.
Right arrow Articles by Stark, G. R.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Role of Tyrosine 441 of Interferon-{gamma} Receptor Subunit 1 in SOCS-1-mediated Attenuation of STAT1 Activation*

Yulan Qing{ddagger}§, Ana P. Costa-Pereira¶, Diane Watling¶, and George R. Stark{ddagger}§||

From the {ddagger}Department of Molecular Biology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, §Department of Genetics, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, and Cancer Research UK, London Research Institute, Lincoln's Inn Laboratories, London WC2A 3PX, United Kingdom

Received for publication, August 26, 2004 , and in revised form, October 27, 2004.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Suppressor of cytokine signaling (SOCS)-1, the key negative regulator of interferon (IFN)-{gamma}-dependent signaling, is induced in response to IFN{gamma}. SOCS-1 binds to and inhibits the IFN{gamma} receptor-associated kinase Janus-activated kinase (JAK) 2 and inhibits its function in vitro, but the mechanism by which SOCS-1 inhibits IFN{gamma}-dependent signaling in vivo is not clear. Upon stimulation, mouse IFN{gamma} receptor subunit 1 (IFNGR1) is phosphorylated on several cytoplasmic tyrosine residues, and Tyr419 is required for signal transducer and activator of transcription (STAT) 1 activation in mouse embryo fibroblasts. However, the functions of the other three cytoplasmic tyrosine residues are not known. Here we show that Tyr441 is required to attenuate STAT1 activation in response to IFN{gamma}. Several tyrosine to phenylalanine mutants of IFNGR1, expressed at normal levels in stable pools of IFNGR1-null cells, were analyzed for the phosphorylation of STAT1 during a 48-h period, and antiviral activity in response to IFN{gamma} was also measured. Stronger activation of STAT1 was observed in cells expressing all IFNGR1 variants mutated at Tyr441, and, consistently, stronger antiviral activity was also observed in these cells. Furthermore, constitutive overexpression of SOCS-1 inhibited IFN{gamma}-dependent signaling only in cells expressing IFNGR1 variants that included the Tyr441 mutation. Mutation of Tyr441 also blocked the ability of SOCS-1 to bind to IFNGR1 and JAK2 in response to IFN{gamma} and the normal down-regulation of STAT1 activation and antiviral activity. These results, together with data from the literature, suggest a model in which, in response to IFN{gamma}, phosphorylation of Tyr441 creates a docking site for SOCS-1, which then binds to JAK2 within the receptor-JAK complex to partially inhibit JAK2 phosphorylation. Furthermore, the virtually complete blockade of STAT1 phosphorylation by overexpressed SOCS-1 in this experiment suggests that the binding of SOCS-1 to Tyr441 also blocks the access of STAT1 to Tyr419 and that this effect may be the principal mechanism of inhibition of downstream signaling.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Interferon (IFN)1-{gamma} plays key roles in mediating antiviral and antigrowth responses and in modulating immune responses (1). The major signal transduction pathway activated by IFN{gamma} has been elucidated through both biochemical and genetic studies. The IFN{gamma} receptor complex consists of two receptor subunits, IFNGR1 and IFNGR2, and the tyrosine kinases Janus-activated kinase (JAK) 1 and JAK2, which bind to IFNGR1 and IFNGR2, respectively. IFN{gamma} induces the oligomerization of the receptor subunits, leading to the activation of JAK1 and JAK2, which then phosphorylate tyrosine residues within the cytoplasmic domain of IFNGR1. Signal transducer and activator of transcription (STAT) 1 is then recruited to the receptor complex and phosphorylated on Tyr701, allowing it to be released, form homodimers, translocate to the nucleus, and bind to {gamma}-activated sequences to activate the transcription of interferon-stimulated genes (ISGs) (1–3).

The activation of STAT1 by IFN{gamma} is tightly controlled by several mechanisms (4). The SH2-containing phosphatase 2 binds to IFNGR1 and inhibits STAT1 activation without inhibiting the phosphorylation of IFNGR1 (5). Protein inhibitor of activated STAT 1 (PIAS-1) binds to STAT1 and prevents its association with target DNA (6). Both genetic and biochemical studies have shown that suppressor of cytokine signaling (SOCS)-1 is the most potent inhibitor of IFN{gamma} signaling (7). Mice lacking SOCS-1 develop a complex fatal neonatal disease (8–10), and the mortality, which results from hypersensitivity to IFN{gamma}, is largely prevented by administration of anti-IFN{gamma}. In addition, premature death does not occur in mice lacking both SOCS-1 and IFN{gamma} (9, 11). In response to IFN{gamma}, STAT1 activation is much stronger in cells lacking SOCS-1 than in wild-type cells (11, 12). The constitutive expression of SOCS-1 blocks IFN{gamma}-mediated antiviral and antiproliferative activities (13), and in vitro studies have shown that the SOCS-1 protein inhibits the kinase activity of JAK2 by binding directly to the active site loop domain (14). SOCS-1 can also direct proteins to which it binds, including guanine nucleotide exchange factor VAV, insulin receptor substrates 1 and 2, and JAK2, to proteasome-mediated degradation (15–18).

Tyrosine phosphorylation is used by most cell surface receptors to initiate downstream signaling in response to cytokines and growth factors (19–23). Receptor phosphorylation creates docking sites for downstream signaling components and mutation of specific tyrosine residues blocks signal transduction (24–28). The situation for IFN{gamma}-dependent signaling has been well studied. Activation of JAK1 and JAK2 is mediated by trans- and autophosphorylation. Phosphorylated Tyr419 of IFNGR1 creates the docking site for STAT1 in mouse embryo fibroblasts (MEFs), and phosphorylation of Tyr440 of human IFNGR1 has a major role in activating STAT1 and mediating antiviral activity. Tyrosine to phenylalanine mutation of this motif impairs STAT1 activation as well as the expression of ISGs (29, 30).

Tyrosine phosphorylation also provides the basis for negative regulation of receptor-dependent signaling (31–34). For the interleukin-6 family of cytokines, the gp130 receptor subunit is phosphorylated, and four of its cytoplasmic tyrosine residues are involved in the activation of STATs 1 and 3 (35). Furthermore, Tyr759 is required for the binding of SH2-containing phosphatase 2 and SOCS-3 (36, 37). SH2-containing phosphatase 2 mediates the activation of mitogen-activated protein kinase in pro-B cell lines (38) and negatively regulates STAT activation in gp130-dependent signaling (39); SOCS-3 is the key negative regulator of gp130-dependent signaling (40–42). Mutation of Tyr759 to phenylalanine enhances signal transduction in response to gp130-linked cytokines, including interleukin-6, leukemia inhibitory factor, and oncostatin M (43, 44). Furthermore, mice expressing a gp130 mutant lacking Tyr759 have splenomegaly, lymphadenopathy, and an enhanced acute phase reaction (45). Here, we investigate the involvement of specific tyrosine residues of IFNGR1 in IFN{gamma}-dependent signaling and find that Tyr441 is required for attenuation. Tyrosine to phenylalanine mutation of this residue leads to stronger STAT1 activation and antiviral activity, and inhibition of signaling in response to SOCS-1 requires Tyr441, as does the IFN{gamma}-dependent binding of SOCS-1 to IFNGR1 and JAK2.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Constructs—Plasmids expressing murine IFNGR1 and the IFNGR1 mutant Y419F were kindly provided by Dr. Robert Schreiber (Washington University, St. Louis, MO). IFNGR1 and IFNGR1 Y419F cDNAs were subcloned into pBABEpuro3. Tyrosine to phenylalanine mutations of IFNGR1 were generated by PCR-splicing overlapping extension (46). The identity of each plasmid was confirmed by DNA sequencing. The plasmid encoding SOCS-1, kindly provided by Dr. Ke Shuai (University of California Los Angeles, Los Angeles, CA), was used to subclone this gene into pBluescript at the XbaI site and then into pLHCX at the HindIII and HpaI sites.

Biological Reagents and Cell Culture—Recombinant murine IFN{gamma} (PeproTech, Inc., Rocky Hill, NJ) was used at 1000 IU/ml. Bosc cells (American Type Culture Collection), wild-type MEFs, and IFNGR1-null MEFs (from Dr. Robert Schreiber) (47) were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, 100 µg/ml penicillin G, and 100 µg/ml streptomycin. Virus-infected cells were maintained in complete medium plus 2 µg/ml puromycin or 100 µg/ml hygromycin.

Western Analyses—After treatment, cells at 80% confluence in 100-mm dishes were washed once with phosphate-buffered saline, and the cell pellets were lysed for 20 min at 4 °C in 100 µl of lysis buffer containing 1% Triton X-100, 50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 10% glycerol, 0.1 mM EDTA, 10 mM sodium fluoride, 1 mM sodium orthovanadate, 1 mM phenylmethanesulfonyl fluoride, 3 µg/ml aprotinin, 2 µg/ml pepstatin, and 1 µg/ml leupeptin. Cellular debris was pelleted by centrifugation at 16,000 x g at 4 °C for 10 min. Cell extracts were fractionated by electrophoresis in 10% SDS-polyacrylamide gels and transferred to nitrocellulose membranes. The following antibodies were used: anti-phospho-Tyr701 STAT1 (Upstate Biotechnology), anti-N-terminal STAT1 (Transduction Laboratories), anti-phospho-JAK2 (BIOSOURCE), anti-phospho-JAK1 (BIOSOURCE), anti-IFNGR1 (Santa Cruz Biotechnology), anti-FLAG (Sigma), and anti-actin (Neomarkers). Horseradish peroxidase-coupled goat anti-rabbit or goat anti-mouse immunoglobulin was used for visualization, using the enhanced chemiluminescence Western detection system (PerkinElmer Life Sciences).

Northern Analyses—Total RNA was isolated by using the TRIzol reagent (Invitrogen). The RNA (15 µg) was denatured, separated by electrophoresis in a formaldehyde-1.2% agarose gel, and transferred to Hybond-N+ nylon membranes (Amersham Biosciences). Socs-3, ip-10, irf-1, and glyceraldehyde-3-phosphate dehydrogenase (gapdh) mRNAs were detected by using cDNAs labeled with [32P]dCTP (Amersham Biosciences) by nick-translation (Megaprime DNA Labeling System; Amersham Biosciences) and visualized by autoradiography.

Antiviral Assays—Cells seeded into 96-well plates at 2 x 104 cells/well were incubated overnight at 37 °C and treated with serial 10-fold dilutions of IFN{gamma} for 18 h. Where indicated, the cells were challenged for 20 h with encephalomyocarditis virus (0.5 plaque-forming unit/cell), fixed, and stained with Giemsa.

Coimmunoprecipitation—After treatment, cells at 80% confluence in 150-mm dishes were washed once with phosphate-buffered saline, and cell pellets were lysed for 20 min at 4 °C in 1 ml of buffer containing 0.5% Triton X-100, 50 mM HEPES, pH 7.4, 150 mM NaCl, 15 mM MgCl2, 0.1 mM EGTA, 10 mM sodium fluoride, 1 mM sodium orthovanadate, 1 mM phenylmethanesulfonyl fluoride, 3 µg/ml aprotinin, 2 µg/ml pepstatin, and 1 µg/ml leupeptin. Cellular debris was pelleted by centrifugation at 16,000 x g at 4 °C for 10 min. Cell lysates were incubated with anti-FLAG antibody and protein G-Sepharose (Amersham Biosciences) overnight. Immunoprecipitates were washed four times with ice-cold lysis buffer and analyzed by the Western method.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
Tyrosine Residues of IFNGR1 Provide Negative Regulation of IFN{gamma}-dependent Signaling—Mouse IFNGR1 has four cytoplasmic tyrosine residues, which are phosphorylated upon stimulation with IFN{gamma}. Tyr419 is required for the activation of STAT1 (46, 47), but the functions of the other tyrosines are not known. Previous studies have shown that Tyr759 of gp130, which is not needed for STAT3 activation, is required for the negative regulation of this process (36, 37, 39). To reveal whether a tyrosine residue of IFNGR1 other than Tyr419 is similarly required for the negative regulation of IFN{gamma}-dependent signaling, IFNGR1-null cells expressing either wild-type or 3F/419Y IFNGR1 (three of the four cytoplasmic tyrosine residues were mutated to phenylalanines) were used to examine the phosphorylation on tyrosine of STAT1, which was stronger in cells expressing 3F/419Y than in cells expressing wild-type IFNGR1 (Fig. 1a). Because phosphorylated STAT1 is essential for the transcription of most IFN{gamma}-induced genes, the expression of three ISGs was also examined. After treatment with IFN{gamma}, the levels of irf-1, ip-10, and socs-3 mRNAs were increased by 2-fold or more in cells expressing 3F/419Y compared with cells expressing wild-type IFNGR1 (Fig. 1b). Therefore, STAT1 activation is negatively regulated by a tyrosine residue other than Tyr419 of IFNGR1.



View larger version (59K):
[in this window]
[in a new window]
  		FIG. 1.
Tyrosine residues are involved in regulating STAT1 phosphorylation and ISG expression. a, cells expressing wild-type (WT) IFNGR1 or the 3F/419Y mutant were treated with IFN{gamma} for 0.25, 0.5, 1, 6, or 16 h. Total cell lysates were analyzed by the Western method, using antibodies against phospho-STAT1 (pYSTAT1) and actin. b, cells expressing wild-type (WT) IFNGR1 or the 3F/419Y mutant were treated with IFN{gamma} for 4 h. Total RNA was isolated and analyzed by the Northern method.

 
Tyr441 of IFNGR1 Is Required for Negative Regulation of STAT1 Activation in Response to IFN{gamma}—To determine which tyrosine(s) might be required, several different tyrosine to phenylalanine mutants were generated (Fig. 2). In mutant 2F/441Y/419Y, STAT1 phosphorylation was attenuated normally, and the attenuation was abolished in all mutants that include Y441F (Fig. 3a). Note that the basal levels of STAT1 in these cells are very low. Detailed time courses with single tyrosine to phenylalanine mutants confirmed that Tyr441 is the primary residue that mediates negative regulation of STAT1 activation in response to IFN{gamma} (Fig. 3b). To test whether Tyr441 is also involved in modulating the antiviral response, an assay was performed to assess the ability of IFN{gamma} to protect cells from the cytopathic effects of encephalomyocarditis virus in cells expressing wild-type IFNGR1 or several mutants. Cells expressing the 3F/419Y, 2F/285Y/419Y, or 2F/370Y/419Y mutants of IFNGR1 were protected at much lower doses of IFN{gamma} than were cells expressing wild-type IFNGR1 or the 2F/441Y/419Y mutant (Fig. 3c). These data provide additional evidence that Tyr441 of IFNGR1 mediates the negative regulation of IFN{gamma}-dependent signaling, including antiviral activity.



View larger version (45K):
[in this window]
[in a new window]
  		FIG. 2.
Expression levels of IFNGR1 mutants. a, diagram of the cytoplasmic domain of IFNGR1 and of the tyrosine to phenylalanine mutants studied. The four cytoplasmic tyrosines of IFNGR1, which are conserved between human and mouse, were mutagenized to produce 16 different mutants, 8 of which were used in this study. b, expression levels of IFNGR1 tyrosine mutants. IFNGR1-null MEFs were infected with empty vector pBABEpuro3 or with vector including DNA for expression of various mutants of IFNGR1, and pools of cells stably expressing the different IFNGR1s were selected. Total cell lysates, together with lysates from wild-type (WT) MEFs, were analyzed by the Western method using antibodies against IFNGR1 and actin.

 



View larger version (51K):
[in this window]
[in a new window]
  		FIG. 3.
Tyr441 is required to attenuate IFN{gamma} signaling. a, cells expressing various mutants of IFNGR1 were treated with IFN{gamma} for 24 h. Total cell lysates were prepared and analyzed by the Western method, using antibodies against phospho-STAT1 (pYSTAT1), total STAT1, and actin. Note that the basal level of STAT1 is very low in these cells. b, kinetics of STAT1 activation in response to IFN{gamma} in cells expressing wild-type (WT) IFNGR1 or the 3F/419Y, 2F/441Y/419Y, and 3Y/441F mutants. c, IFN{gamma}-induced antiviral responses in cells expressing wild-type (WT) IFNGR1 or the 2F/285Y/419Y, 2F/370Y/419Y, and 2F/441Y/419Y mutants. Cells were incubated with the indicated concentrations of IFN{gamma} for 18 h before infection with encephalomyocarditis virus for 20 h, and live cells were stained. C, control (medium only); V, virus-infected, no IFN{gamma}.

 
Inhibition of IFN{gamma}-dependent Signaling by SOCS-1 Is Mediated by Tyr441—Previous studies identified SOCS-1 as a critical inhibitor of IFN{gamma}-dependent signaling (7); SOCS-1 was expressed constitutively in cells with wild-type IFNGR1 or the 3F/419Y, 2F/441Y/419Y, and 3Y/441F mutants, and responses to IFN{gamma} were examined. SOCS-1 blocked STAT1 phosphorylation virtually completely, but only in cells expressing wild-type IFNGR1 or the 2F/441Y/419Y mutant, and not in cells expressing the 3F/419Y or 3Y/441F mutants (Fig. 4a). Constitutive overexpression of SOCS-1 attenuated the IFN{gamma}-dependent phosphorylation of JAK2 by about 2-fold in cells expressing wild-type IFNGR1 or the 2F/441Y/419Y mutant, but not in cells expressing the 3F/419Y or 3Y/441F mutants, and the phosphorylation of JAK1 was intact (Fig. 4b). Protein levels of JAK1 and JAK2 did not change during the time course investigated (data not shown).



View larger version (46K):
[in this window]
[in a new window]
  		FIG. 4.
SOCS-1-mediated inhibition of IFN{gamma} signaling requires Tyr441. a, cells expressing wild-type (WT) IFNGR1 or the 3F/419Y, 2F/441Y/419Y, and 3Y/441F mutants were infected with empty vector pLHCX or with pLHCX containing DNA for expression of FLAG-tagged SOCS-1, and stable pools of cells were generated and treated with IFN{gamma} for 30 min. Total cell lysates were prepared and analyzed by the Western method, using antibodies against phospho-STAT1 (pYSTAT1), FLAG, and actin. b, kinetics of JAK1 and JAK2 phosphorylation in response to IFN{gamma}. c, effect of SOCS-1 on IFN{gamma}-induced antiviral responses in cells expressing wild-type (WT) IFNGR1 or the 3F/419Y, 2F/441Y/419Y, and 3Y/441F mutants. Antiviral assays were performed as described in the legend to Fig. 3c.

 
Previous studies have shown that SOCS-1-null mice are more resistant to viral infection than are wild-type mice (11) and, conversely, that overexpression of SOCS-1 completely blocks the antiviral activity of IFN{gamma} (13). Constitutively overexpressed SOCS-1 abrogated antiviral responses in cells expressing wild-type IFNGR1 or the 2F/441Y/419Y mutant but did not inhibit this response in cells carrying the 3F/419Y or 3Y/441F mutants of IFNGR1. Consistent with these results, IFN{gamma} protected cells expressing the 3F/419Y or 3Y/441F mutants of IFNGR1 at lower doses than cells with wild-type IFNGR1 or the 2F/441Y/419Y mutant (Fig. 4c). These results indicate that Tyr441 is required to mediate the inhibitory effect of SOCS-1 in IFN{gamma}-dependent signaling.

Tyr441 Is Required for the IFN{gamma}-dependent Association of SOCS-1 and IFNGR1—The results cited above show that inhibition of IFN{gamma}-dependent signaling by SOCS-1 requires Tyr441 of IFNGR1. Does SOCS-1 bind to IFNGR1, and, if so, does binding require Tyr441? Coimmunoprecipitation Western analysis showed that, in response to IFN{gamma}, association was observed only in cells expressing wild-type IFNGR1 or the 2F/441Y/419Y mutant, and not in cells with the 3F/419Y or 3Y/441F mutants. In addition, association of SOCS-1 and JAK2 was also observed only in cells with wild-type IFNGR1 or the 2F/441Y/419Y mutant (Fig. 5). These data indicate that SOCS-1 is recruited to the IFN{gamma} receptor complex in a ligand-dependent manner and that Tyr441 is required for this association.



View larger version (56K):
[in this window]
[in a new window]
  		FIG. 5.
Association of SOCS-1 and IFNGR1 or JAK2 requires Tyr441. Cells with wild-type (WT) IFNGR1 or the 3F/419Y, 2F/441Y/419Y, and 3Y/441F mutants, all overexpressing FLAG-tagged SOCS-1, were treated with IFN{gamma} for 10 min. Total cell lysates were prepared and incubated with anti-FLAG antibody and protein G-Sepharose beads. Immunocomplexes were separated by SDS-PAGE and analyzed by the Western method, using antibodies against IFNGR1, phospho-JAK2 (pYJAK2), and FLAG.

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
Contribution of Specific Tyrosine Residues of IFNGR1 to IFN{gamma}-dependent Signaling—In response to IFN{gamma}, the phosphorylation of Tyr419 of murine IFNGR1 is absolutely required for STAT1 activation (46), the antiviral response (Fig. 3c), and the transcription of ISGs in reconstituted IFNGR1-null MEFs.2 It is interesting that the requirement for the corresponding tyrosine residue of human IFNGR1, Tyr440, appears to be different: in primary human fibroblasts lacking IFNGR1 and reconstituted with the Y440F mutant, the expression of ISGs in response to IFN{gamma} was substantial, although the antiviral effect was inhibited.3 The hybrid murine fibroblast cell line SCC16-5, containing a single copy of human chromosome 21 encoding human IFNGR2, was used initially to characterize human IFNGR1 (49, 50). The expression of various mutants of IFNGR1 in these cells revealed that Tyr440 is required for STAT1 activation and antiviral activity (29, 51). These results, taken together, suggest that cellular backgrounds affect the nature of IFNGR1-dependent signals as well as the responses to IFN{gamma}.

When the Y440F mutant of human IFNGR1 was expressed in SCC16-5 cells, or when the Y419F mutant of mouse IFNGR1 was expressed in IFNGR1-null MEFs, substantial tyrosine phosphorylation of IFNGR1 in response to IFN{gamma} was still observed (29) (data not shown). The functions of the other phosphorylated tyrosine residues of IFNGR1 have not been investigated until now. Here we show that an important function of one of these residues is attenuation of IFN{gamma}-dependent responses, which are stronger in IFNGR1-null MEFs expressing the 3F/419Y mutant than in cells expressing wild-type IFNGR1 (Figs. 1 and 3c). Stronger STAT1 activation in response to IFN{gamma} was also observed in SCC16-5 cells expressing the 4F/440Y mutant, in which four of the five tyrosines in the cytoplasmic domain of IFNGR1 were mutated to phenylalanines, than in cells with wild-type human IFNGR1 (data not shown). Moreover, Tyr441 is the primary residue that mediates this attenuation (Fig. 3). Therefore, IFNGR1 uses different tyrosine residues to provide activation and feedback inhibition signals. Mutant IFNGR1 constructs were made in a retroviral expression vector, and pools of IFNGR1-null cells were generated by infection, followed by selection with puromycin. By titering the viruses, relatively even expression of different mutant IFNGR1s was achieved, at levels matching that of IFNGR1 in wild-type cells (Fig. 2). We believe that it is advantageous to use stable pools of cells, allowing one to observe an average response and to avoid being misled by differences among different cell clones.

Interaction of SOCS-1 and IFNGR1—Analyses of the mechanisms of the inhibitory effects of SOCS-1 have focused on the ability of SOCS-1 to bind to the active loop of JAKs, and interaction of SOCS-1 with the interleukin-2 receptor {beta} chain has been shown not to be required for inhibitory effects (52). Our results show that, in IFN{gamma}-dependent signaling, constitutive overexpression of SOCS-1 partially inhibited JAK2 phosphorylation (Fig. 4b), and this inhibition was observed only in cells retaining Tyr441 of IFNGR1. We were also able to show that SOCS-1 binds to IFNGR1 at Tyr441 in a ligand-dependent manner, presumably through an interaction between its SH2 domain and phospho-tyrosine 441, because tyrosine to phenylalanine mutation of Tyr441 abolishes the interaction (Fig. 5). These results, together with others in the literature, suggest that SOCS-1, like SOCS-3 (the most homologous member of the SOCS family) (53), is likely to inhibit cytokine-dependent signaling though its interaction with a receptor (7, 31, 34), although SOCS-1 does interact with and inhibit JAKs in vitro (14, 48).

How SOCS-1 Inhibits IFN{gamma}-dependent Signaling—Studies in vitro have shown that SOCS-1 inhibits the kinase activity of JAK2, probably by binding to the active site loop (14, 53), and the binding of SOCS-1 may also target JAK2 for proteasome-dependent degradation (7). Our results show that SOCS-1 binds to JAK2 only in cells expressing wild-type IFNGR1 or the 2F/441Y/419Y mutant and that mutation of Tyr441 completely abrogates the IFN{gamma}-induced binding of SOCS-1 to IFNGR1 and JAK2 (Fig. 5). Consistently, in cells expressing the 3Y/441F or 3F/419Y mutant of IFNGR1, IFN{gamma}-dependent signaling was prolonged, revealing that the interaction of SOCS-1 and Tyr441 of IFNGR1 is required for negative regulation. A likely scenario is that, in response to IFN{gamma}, SOCS-1 expression is induced, and SOCS-1 is recruited to IFNGR1 through phospho-tyrosine 441, which brings it close enough to JAK2 to enable it to bind to the active site loop, thus inhibiting the kinase activity and possibly also catalyzing proteasome-mediated degradation of JAK2, leading to negative feedback of IFN{gamma}-dependent signaling. However, the relatively small effect on JAK2 phosphorylation contrasts with the dramatic effect on STAT1 phosphorylation. Therefore, it seems likely that a second mechanism is more important in vivo, namely, the binding of SOCS-1 to Tyr441 of IFNGR1 blocks the access of STAT1 to Tyr419, thus preventing STAT1 activation.


   FOOTNOTES
 
* This work was supported by National Institutes of Health Grant PO1 CA62220 (to G. R. S.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

|| To whom correspondence should be addressed: Dept. of Molecular Biology, Lerner Research Institute, The Cleveland Clinic Foundation, 9500 Euclid Ave., Cleveland, OH 44195. Tel.: 216-444-6062; Fax: 216-444-3279; E-mail: starkg{at}ccf.org.

1 The abbreviations used are: IFN, interferon; JAK, Janus-activated kinase; STAT, signal transducer and activator of transcription; SOCS, suppressor of cytokine signaling; MEF, mouse embryo fibroblast; ISG, interferon-stimulated gene; SH, Src homology. Back

2 Y. Qing and G. R. Stark, unpublished data. Back

3 A. P. Costa-Pereira, D. Watling, and I. M. Kerr, unpublished data. Back


   ACKNOWLEDGMENTS
 
We thank Dr. Robert D. Schreiber for providing IFNGR1-null cells, Dr. Ian M. Kerr for critical reading of the manuscript, Dr. Mark Jackson for technical help with retroviral infections, and Drs. Anette van Boxel-Dezaire and Xudong Liao for helpful discussions.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Stark, G. R., Kerr, I. M., Williams, B. R., Silverman, R. H., and Schreiber, R. D. (1998) Annu. Rev. Biochem. 67, 227–264[CrossRef][Medline] [Order article via Infotrieve]
  2. Schindler, C., and Darnell, J. E., Jr. (1995) Annu. Rev. Biochem. 64, 621–651[Medline] [Order article via Infotrieve]
  3. Bach, E. A., Aguet, M., and Schreiber, R. D. (1997) Annu. Rev. Immunol. 15, 563–591[CrossRef][Medline] [Order article via Infotrieve]
  4. Wormald, S., and Hilton, D. J. (2004) J. Biol. Chem. 279, 821–824[Abstract/Free Full Text]
  5. You, M., Yu, D. H., and Feng, G. S. (1999) Mol. Cell. Biol. 19, 2416–2424[Abstract/Free Full Text]
  6. Liu, B., Liao, J., Rao, X., Kushner, S. A., Chung, C. D., Chang, D. D., and Shuai, K. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 10626–10631[Abstract/Free Full Text]
  7. Alexander, W. S., and Hilton, D. J. (2004) Annu. Rev. Immunol. 22, 503–529[CrossRef][Medline] [Order article via Infotrieve]
  8. Starr, R., Metcalf, D., Elefanty, A. G., Brysha, M., Willson, T. A., Nicola, N. A., Hilton, D. J., and Alexander, W. S. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 14395–14399[Abstract/Free Full Text]
  9. Marine, J. C., Topham, D. J., McKay, C., Wang, D., Parganas, E., Stravopodis, D., Yoshimura, A., and Ihle, J. N. (1999) Cell 98, 609–616[CrossRef][Medline] [Order article via Infotrieve]
  10. Naka, T., Matsumoto, T., Narazaki, M., Fujimoto, M., Morita, Y., Ohsawa, Y., Saito, H., Nagasawa, T., Uchiyama, Y., and Kishimoto, T. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 15577–15582[Abstract/Free Full Text]
  11. Alexander, W. S., Starr, R., Fenner, J. E., Scott, C. L., Handman, E., Sprigg, N. S., Corbin, J. E., Cornish, A. L., Darwiche, R., Owczarek, C. M., Kay, T. W., Nicola, N. A., Hertzog, P. J., Metcalf, D., and Hilton, D. J. (1999) Cell 98, 597–608[CrossRef][Medline] [Order article via Infotrieve]
  12. Brysha, M., Zhang, J. G., Bertolino, P., Corbin, J. E., Alexander, W. S., Nicola, N. A., Hilton, D. J., and Starr, R. (2001) J. Biol. Chem. 276, 22086–22089[Abstract/Free Full Text]
  13. Song, M. M., and Shuai, K. (1998) J. Biol. Chem. 273, 35056–35062[Abstract/Free Full Text]
  14. Yasukawa, H., Misawa, H., Sakamoto, H., Masuhara, M., Sasaki, A., Wakioka, T., Ohtsuka, S., Imaizumi, T., Matsuda, T., Ihle, J. N., and Yoshimura, A. (1999) EMBO J. 18, 1309–1320[CrossRef][Medline] [Order article via Infotrieve]
  15. Ungureanu, D., Saharinen, P., Junttila, I., Hilton, D. J., and Silvennoinen, O. (2002) Mol. Cell. Biol. 22, 3316–3326[Abstract/Free Full Text]
  16. Kamizono, S., Hanada, T., Yasukawa, H., Minoguchi, S., Kato, R., Minoguchi, M., Hattori, K., Hatakeyama, S., Yada, M., Morita, S., Kitamura, T., Kato, H., Nakayama, K., and Yoshimura, A. (2001) J. Biol. Chem. 276, 12530–12538[Abstract/Free Full Text]
  17. Rui, L., Yuan, M., Frantz, D., Shoelson, S., and White, M. F. (2002) J. Biol. Chem. 277, 42394–42398[Abstract/Free Full Text]
  18. De Sepulveda, P., Ilangumaran, S., and Rottapel, R. (2000) J. Biol. Chem. 275, 14005–14008[Abstract/Free Full Text]
  19. Jiang, G., and Hunter, T. (1999) Curr. Biol. 9, R568–R571[CrossRef][Medline] [Order article via Infotrieve]
  20. Heldin, C. H. (1995) Cell 80, 213–223[CrossRef][Medline] [Order article via Infotrieve]
  21. van der Geer, P., Hunter, T., and Lindberg, R. A. (1994) Annu. Rev. Cell Biol. 10, 251–337[CrossRef][Medline] [Order article via Infotrieve]
  22. Ihle, J. N. (1995) Nature 377, 591–594[CrossRef][Medline] [Order article via Infotrieve]
  23. Karnitz, L. M., and Abraham, R. T. (1995) Curr. Opin. Immunol. 7, 320–326[CrossRef][Medline] [Order article via Infotrieve]
  24. Mulcahy, L. (2001) Semin. Oncol. 28, 19–23[Medline] [Order article via Infotrieve]
  25. Zhu, T., Goh, E. L., Graichen, R., Ling, L., and Lobie, P. E. (2001) Cell Signal. 13, 599–616[CrossRef][Medline] [Order article via Infotrieve]
  26. Heldin, C. H., and Westermark, B. (1999) Physiol. Rev. 79, 1283–1316[Abstract/Free Full Text]
  27. Jorissen, R. N., Walker, F., Pouliot, N., Garrett, T. P., Ward, C. W., and Burgess, A. W. (2003) Exp. Cell Res. 284, 31–53[CrossRef][Medline] [Order article via Infotrieve]
  28. Klint, P., and Claesson-Welsh, L. (1999) Front. Biosci. 4, D165–D177[Medline] [Order article via Infotrieve]
  29. Greenlund, A. C., Farrar, M. A., Viviano, B. L., and Schreiber, R. D. (1994) EMBO J. 13, 1591–1600[Medline] [Order article via Infotrieve]
  30. Strobl, B., Arulampalam, V., Is'harc, H., Newman, S. J., Schlaak, J. F., Watling, D., Costa-Pereira, A. P., Schaper, F., Behrmann, I., Sheehan, K. C., Schreiber, R. D., Horn, F., Heinrich, P. C., and Kerr, I. M. (2001) EMBO J. 20, 5431–5442[CrossRef][Medline] [Order article via Infotrieve]
  31. Sasaki, A., Yasukawa, H., Shouda, T., Kitamura, T., Dikic, I., and Yoshimura, A. (2000) J. Biol. Chem. 275, 29338–29347[Abstract/Free Full Text]
  32. Stofega, M. R., Herrington, J., Billestrup, N., and Carter-Su, C. (2000) Mol. Endocrinol. 14, 1338–1350[Abstract/Free Full Text]
  33. Heinrich, P. C., Behrmann, I., Haan, S., Hermanns, H. M., Muller-Newen, G., and Schaper, F. (2003) Biochem. J. 374, 1–20[CrossRef][Medline] [Order article via Infotrieve]
  34. Hortner, M., Nielsch, U., Mayr, L. M., Johnston, J. A., Heinrich, P. C., and Haan, S. (2002) J. Immunol. 169, 1219–1227[Abstract/Free Full Text]
  35. Gerhartz, C., Heesel, B., Sasse, J., Hemmann, U., Landgraf, C., Schneider-Mergener, J., Horn, F., Heinrich, P. C., and Graeve, L. (1996) J. Biol. Chem. 271, 12991–12998[Abstract/Free Full Text]
  36. Nicholson, S. E., De Souza, D., Fabri, L. J., Corbin, J., Willson, T. A., Zhang, J. G., Silva, A., Asimakis, M., Farley, A., Nash, A. D., Metcalf, D., Hilton, D. J., Nicola, N. A., and Baca, M. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 6493–6498[Abstract/Free Full Text]
  37. Schmitz, J., Weissenbach, M., Haan, S., Heinrich, P. C., and Schaper, F. (2000) J. Biol. Chem. 275, 12848–12856[Abstract/Free Full Text]
  38. Fukada, T., Hibi, M., Yamanaka, Y., Takahashi-Tezuka, M., Fujitani, Y., Yamaguchi, T., Nakajima, K., and Hirano, T. (1996) Immunity 5, 449–460[CrossRef][Medline] [Order article via Infotrieve]
  39. Symes, A., Stahl, N., Reeves, S. A., Farruggella, T., Servidei, T., Gearan, T., Yancopoulos, G., and Fink, J. S. (1997) Curr. Biol. 7, 697–700[CrossRef][Medline] [Order article via Infotrieve]
  40. Yasukawa, H., Ohishi, M., Mori, H., Murakami, M., Chinen, T., Aki, D., Hanada, T., Takeda, K., Akira, S., Hoshijima, M., Hirano, T., Chien, K. R., and Yoshimura, A. (2003) Nat. Immunol. 4, 551–556[CrossRef][Medline] [Order article via Infotrieve]
  41. Lang, R., Pauleau, A. L., Parganas, E., Takahashi, Y., Mages, J., Ihle, J. N., Rutschman, R., and Murray, P. J. (2003) Nat. Immunol. 4, 546–550[CrossRef][Medline] [Order article via Infotrieve]
  42. Croker, B. A., Krebs, D. L., Zhang, J. G., Wormald, S., Willson, T. A., Stanley, E. G., Robb, L., Greenhalgh, C. J., Forster, I., Clausen, B. E., Nicola, N. A., Metcalf, D., Hilton, D. J., Roberts, A. W., and Alexander, W. S. (2003) Nat. Immunol. 4, 540–545[CrossRef][Medline] [Order article via Infotrieve]
  43. Anhuf, D., Weissenbach, M., Schmitz, J., Sobota, R., Hermanns, H. M., Radtke, S., Linnemann, S., Behrmann, I., Heinrich, P. C., and Schaper, F. (2000) J. Immunol. 165, 2535–2543[Abstract/Free Full Text]
  44. Schaper, F., Gendo, C., Eck, M., Schmitz, J., Grimm, C., Anhuf, D., Kerr, I. M., and Heinrich, P. C. (1998) Biochem. J. 335, 557–565[Medline] [Order article via Infotrieve]
  45. Ohtani, T., Ishihara, K., Atsumi, T., Nishida, K., Kaneko, Y., Miyata, T., Itoh, S., Narimatsu, M., Maeda, H., Fukada, T., Itoh, M., Okano, H., Hibi, M., and Hirano, T. (2000) Immunity 12, 95–105[CrossRef][Medline] [Order article via Infotrieve]
  46. Qing, Y., and Stark, G. R. (2004) J. Biol. Chem. 279, 41679–41685[Abstract/Free Full Text]
  47. Woldman, I., Varinou, L., Ramsauer, K., Rapp, B., and Decker, T. (2001) J. Biol. Chem. 276, 45722–45728[Abstract/Free Full Text]
  48. Sasaki, A., Yasukawa, H., Suzuki, A., Kamizono, S., Syoda, T., Kinjyo, I., Sasaki, M., Johnston, J. A., and Yoshimura, A. (1999) Genes Cells 4, 339–351[Abstract]
  49. Janssen, J. W., Collard, J. G., Tulp, A., Cox, D., Millington-Ward, A., and Pearson, P. (1986) Cytometry 7, 411–417[CrossRef][Medline] [Order article via Infotrieve]
  50. Jung, V., Rashidbaigi, A., Jones, C., Tischfield, J. A., Shows, T. B., and Pestka, S. (1987) Proc. Natl. Acad. Sci. U. S. A. 84, 4151–4155[Abstract/Free Full Text]
  51. Farrar, M. A., Campbell, J. D., and Schreiber, R. D. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 11706–11710[Abstract/Free Full Text]
  52. Sporri, B., Kovanen, P. E., Sasaki, A., Yoshimura, A., and Leonard, W. J. (2001) Blood 97, 221–226[Abstract/Free Full Text]
  53. Starr, R., Willson, T. A., Viney, E. M., Murray, L. J., Rayner, J. R., Jenkins, B. J., Gonda, T. J., Alexander, W. S., Metcalf, D., Nicola, N. A., and Hilton, D. J. (1997) Nature 387, 917–921[CrossRef][Medline] [Order article via Infotrieve]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Immunol.Home page
C. B. Wilson, M. Ray, M. Lutz, D. Sharda, J. Xu, and P. A. Hankey
The RON Receptor Tyrosine Kinase Regulates IFN-{gamma} Production and Responses in Innate Immunity
J. Immunol., August 15, 2008; 181(4): 2303 - 2310.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. P. Costa-Pereira, H. M. Hermanns, H. Is'harc, T. M. Williams, D. Watling, V. Arulampalam, S. J. Newman, P. C. Heinrich, and I. M. Kerr
Signaling through a Mutant IFN-{gamma} Receptor
J. Immunol., November 1, 2005; 175(9): 5958 - 5965.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. G. Mujtaba, L. O. Flowers, C. B. Patel, R. A. Patel, M. I. Haider, and H. M. Johnson
Treatment of Mice with the Suppressor of Cytokine Signaling-1 Mimetic Peptide, Tyrosine Kinase Inhibitor Peptide, Prevents Development of the Acute Form of Experimental Allergic Encephalomyelitis and Induces Stable Remission in the Chronic Relapsing/Remitting Form
J. Immunol., October 15, 2005; 175(8): 5077 - 5086.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
280/3/1849    most recent
M409863200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Qing, Y.
Right arrow Articles by Stark, G. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Qing, Y.
Right arrow Articles by Stark, G. R.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2005 by the American Society for Biochemistry and Molecular Biology.